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Abstract
Background: There is growing controversy regarding the association between digoxin and 
mortality in atrial fibrillation (AF). The aim of this analysis was to systematically review  
digoxin use and risk of mortality in patients with AF.
Methods: MEDLINE, EMBASE, GoogleScholar, CINAHL, meeting abstracts, presentations, 
and Cochrane central databases were searched from inception through December 2014, without 
language restrictions. For a study to be selected, it had to report the risk of mortality associated 
with digoxin use in AF patients as an outcome measure. Data were extracted by 2 independent 
authors. Evidence tables were created.
Results: A total of 16 studies (6 post hoc analyses of randomized controlled trials) with 
111,978 digoxin users and 389,643 non-digoxin users were included. In a random effects 
model, patients treated with digoxin had a 27% increased risk of all-cause mortality (pooled 
HR 1.27; 95% CI 1.19–1.36) and 21% increased risk of cardiovascular mortality (pooled HR 
1.21; 95% CI 1.12–1.30) compared with those who did not use digoxin. In a random effects 
model, the association of digoxin with all-cause mortality was stronger for AF patients without 
heart failure (pooled HR 1.47; 95% CI 1.25–1.73) than AF patients with heart failure (pooled 
HR 1.21; 95% CI 1.07–1.36, interaction p = 0.06).
Conclusions: Digoxin use in AF is associated with increased risk of all-cause and cardio-
vascular mortalities. The effect size was larger for AF patients without heart failure than AF 
patients with heart failure. The study suggests further directed analyses to study the effect that 
is suggested by this meta-analysis, especially in AF without heart failure. (Cardiol J 2016; 23, 
3: 333–343)
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Introduction
Digoxin is commonly used for rate control in 
atrial fibrillation (AF). Despite a relative paucity 
of data from large randomized controlled trials, 
several guidelines have recommended its use. 
The 2014 American Heart Association/American 
College of Cardiology guidelines suggest the use 
of digoxin alone in sedentary patients (class I, 
level of evidence: C) or in combination with either 
a beta-blocker or non-dihydropyridine calcium 
channel blocker for non-sedentary individuals 
and individuals with heart failure (HF) (class IIA, 
level of evidence: B) [1]. The European Society of 
Cardiology also recommends its long-term use in 
both sedentary and active AF patients (class IIA, 
level of evidence: C) [2]. However, there is grow-
ing controversy regarding the association between 
digoxin and mortality. Earlier investigations of 
digoxin in HF patients did not demonstrate an 
increased risk of mortality with digoxin use [3]. 
However, recent studies suggested an increased 
risk of mortality with digoxin among AF patients 
[4, 5]. It will be difficult to design a randomized 
controlled trial that would evaluate these findings 
and thus a meta-analysis may provide useful in-
sight and information regarding digoxin use in AF 
patients. To evaluate the association of digoxin with 
mortality in AF, we conducted a systematic review 
and meta-analysis to assess whether digoxin use 
in AF patients is independently associated with an 
increased risk of mortality.
Methods
Study design
Protocol. We undertook a systematic review 
and meta-analysis of randomized controlled trials 
and observational studies assessing digoxin use 
in AF patients and its association with mortality.
Data collection. Two reviewers performed an 
electronic search of MEDLINE, EMBASE, Google-
Scholar, Web of Science for published manuscripts 
until December 15, 2014. We reviewed abstracts 
from major cardiology meetings held between 2001 
and 2014. No limits were used for the search. We 
also searched the references of the related articles, 
as well as links to related articles to gather ad-
ditional articles. We also performed an extensive 
search of the narrative reviews of the relevant top-
ics. The search terms included variants of “atrial 
fibrillation”, “atrial flutter”, “atrial arrhythmia”, 
“supraventricular tachycardia”, “digoxin”, “digi-
talis”, “cardiac glycoside”, “digitoxin”, “foxglove”, 
“mortality”, “death”, “outcomes”, “risk factor”, 
“clinical trials”, and “prognosis” using text words 
and Medical Subject Headings (MeSH) terms. We 
also reviewed editorials and letters related to the 
topic to identify published and unpublished data. 
There were no restrictions applied to language, 
publication date, or publication status. The search 
was performed without any language restrictions. 
When an abstract from a meeting and a full article 
referred to the same trial, only the full article was 
included in the analysis. When there were multi-
ple reports from the same trial, we used the most 
complete and/or recently reported data.
Inclusion and exclusion criteria
We included both observational studies and 
analyses from clinical trials. Randomized controlled 
trial was defined according to the National Library 
of Medicine criteria. Atrial fibrillation was defined 
either by electrocardiogram, self-report or inter-
national classification of diseases codes. Studies 
that did not report mortality were excluded. Data 
for each trial were abstracted by an investigator 
(W.T.Q.) and confirmed by a second investigator 
(M.A.). All discrepancies were identified and re-
solved by consensus, or as needed, with a third 
investigator (W.T.O.).
Study quality. We followed the Preferred 
Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines for systematic 
reviews and meta-analyses [6]. We did not use 
a proper scoring system to grade the study quality 
as strongly discouraged by the Cochrane Collabo-
ration [7].
Outcomes. The primary endpoint was all-
cause mortality. The secondary outcome was 
cardiovascular mortality. Data on endpoints were 
abstracted by Waquas Qureshi and Mouaz H. 
Al-Mallah. All disagreements were resolved by 
reaching consensus.
Statistical analysis. For all studies, we ex-
tracted the study baseline characteristics, event 
rates, hazard ratios (HR), and 95% confidence 
intervals (CI) for the primary and secondary out-
comes. We extracted HRs for digoxin use in AF 
patients and all-cause mortality from published 
manuscripts and abstracts. The effect sizes were 
obtained from intention-to-treat analyses and fully 
adjusted models in the cohort studies.
The primary analysis measured the pooled 
estimate of mortality risk associated with digoxin 
use in AF patients. The secondary analysis meas-
ured the pooled estimate of risk for cardiovascular 
mortality. A stratified analysis for individuals with 
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and without HF was also performed as HF patients 
with AF are more likely to be treated with digoxin 
due to its inotropic effect. Since we expected sig-
nificant heterogeneity in the results, we also per-
formed a pre-specified sensitivity analysis without 
observational studies.
To study heterogeneity, we hypothesized that 
the effect size may differ according to methodologi-
cal quality of the studies. Thus, we used a random 
effects model by DerSimonian and Laird [8]. The 
random effects model assumes that the studies 
included in the meta-analysis are a random sample 
of hypothetical study populations. The random 
effects model provides a more conservative esti-
mate of the combined data with a wider confidence 
interval and the summary statistic is less likely to 
be significant. The heterogeneity was assessed 
using the Cochrane Q statistic and the percentage 
of total variability due to true-between study het-
erogeneity was evaluated by using the I2 measure. 
A p-value < 0.10 was considered significant for 
I2 measure and interaction tests [9].
We performed meta-regression to examine 
if the natural log-transformed HR of the effect of 
digoxin use on mortality was influenced by the 
prevalence of HF.  We used an unrestricted maximal 
likelihood method for mixed effects regression to 
evaluate for slope significance.
We assessed publication bias subjectively by 
visual inspection of Begg’s funnel plot [10] and 
objectively by Egger’s regression asymmetry test 
as funnel plots may be inaccurate in the assess-
ment of very large studies [11, 12]. To address 
the possibility that “N” number of studies possibly 
were missing from our analysis and these studies, 
if included in the analysis, would shift the effect 
size towards the null, we used Orwin’s fail-safe 
N formula. If the meta-analysis has captured all the 
relevant studies, then the funnel plot is expected 
to be symmetrical. However, if there is asymme-
try in the plot, it is expected that there are some 
studies missing from the analysis. This asymmetry 
is addressed by Duval and Tweedie “trim and fill” 
method. For example, if there are more studies 
on the right-hand side and fewer studies on the 
left-hand side of the funnel plot, this would raise 
concern that these left-hand studies potentially 
exist. The Duval and Tweedie trim and fill method 
trims the right hand asymmetric studies to calcu-
late an unbiased effect by an iterative procedure. It 
then fills the plot by re-introducing the right hand 
trimmed studies on the right as well as imputed 
counterparts to the left of the mean effect [13]. 
We reported the unbiased effect and the number 
of possible missing studies from the analysis. We 
also performed an additional cumulative analysis 
to evaluate if there was a temporal effect of the 
studies. Additionally, we evaluated removal of 
individual studies on the pooled HR. All analyses 
were performed using RevMan v. 5.0 and Compre-
hensive Meta-Analysis v. 2.2.4.
Results
We identified 1,543 studies during the initial 
literature search. After removing duplicates, 1,242 
studies remained. After reading the abstracts and 
full text of the selected studies, 1,052 studies were 
discarded due to inability to meet inclusion crite-
ria. Full review of 101 manuscripts and abstracts 
was performed and 24 studies were selected, 
6 did not report the desired HRs and effect sizes to 
estimate our primary outcome. One of the studies 
was a patient-level meta-analysis of 4 trials [14]. 
Finally, 16 studies were selected with study data 
of 19 studies in this meta-analysis (Suppl. Fig. 1).
As mentioned above, there were 6 studies out 
of 16 that reported data from 9 clinical trials while 
other studies were observational in nature. There 
was 1 conference presentation and 1 conference 
abstract, while the remaining studies were either 
published or in online print. We used both of them 
separately. Study characteristics are presented in 
Table 1. Studies mainly included males from white 
populations. Hypertension was the most frequent 
risk factor (39–100%) and only 1 study did not 
include patients with HF.
There were a total of 501,681 participants 
(mean age 73.8 years, males 62.3%), of whom 
43,370 were enrolled in clinical trials and 458,311 
included in observational studies. There were 
414,116 patients with AF. There were 111,978 
digoxin users and 389,643 participants who did 
not use digoxin. A breakdown for each study is 
presented in Supplementary Table 1.
Using a random effects model, the risk of mor-
tality was 27% higher in individuals using digoxin 
compared with persons who did not use digoxin 
(pooled HR: 1.27; 95% CI 1.19–1.36, p < 0.001) 
(Fig. 1). When only subgroups of randomized clini-
cal trials were analyzed, the risk for mortality for 
digoxin users increased to 46% (pooled HR: 1.46; 
95% CI 1.09–1.94, p = 0.01) (Fig. 2). There was 
a high degree of heterogeneity in pooled studies 
(c2: 124, df = 14, p < 0.001; I2 = 89%). When only 
studies with older individuals (n = 8; age > 70) 
who had a higher prevalence of HF (> 30%) were 
retained in the analysis, the heterogeneity became 
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Table 1. Characteristics of the included studies.
Study Year Mean  
age  
[years]
Males  
[%]
Hypertension 
[%]
Diabetes  
[%]
Beta-
-blocker 
use [%]
ACE inhi-
bitor/ARB 
use [%]
HF  
[%]
IHD  
[%]
LIFE [28] 1997 67 42 100 13 49 50 1.4 15.3
AFFIRM [15] 2001 70 61 71 20 58 64 8.2 38.1
SPORTIF [29] 2002 71 69 77 24 4 NA 36.6 44.7
RIKS-HIA [4] 2003 68 58 39 25 50 35 37.8 55.9
SCAF [5] 2007 77 55 48 18 50 38 44.7 19.1
Fauchier [23] 2007 74 61 45 17 35 73 43 23
TREAT-AF [30] 2008 72 98 63 29 NA NA 15.6 4.5
ATRIA-CVRN [24] 2009 71 56 78 24 58 44 0 3.7
RACE II [31] 2009 68 66 61 11 70 51 34.5 17.9
ROCKET-AF [32] 2010 73 60 90 40 65 67 54.4 23.3
NHIRD [33] 2010 67 54 66 30 NA NA 10.9 10.1
PALLAS [34] 2010 75 65 85 NA 41 77 54 41
ADONIS [14] 2010 64 69 54 NA 65 41 12.2 24.2
ANDROMEDA [14] 2010 72 79 39 NA 71 83 100 63.3
ATHENA [14] 2010 72 53 86 NA 74 70 21.2 30
ORBIT-AF [35] 2011 68 57 NA NA NA NA 13 16
Quebec study [27] 2012 80 42 62 32 51 61 32.3 NA
AUPD study [36] 2012 73 53 20 8 18 NA 10 9.4
Pastori study [37] 2013 73 57 89 20 41 70 16 23
ACE/ARB — angiotensin converting enzyme/angiotensin receptor blocker; HF — heart failure; IHD — ischemic heart disease; NA — not available;  
LIFE — The Losartan Intervention For Endpoint reduction in hypertension; AFFIRM — the AF Follow-Up Investigation of Rhythm Management; 
SPORTIF — the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation; RIKS-HIA — the Registry of Information and Knowl-
edge about Swedish Heart Intensive care Admissions; SCAF — the Stockholm Cohort-Study of Atrial Fibrillation; TREAT-AF — The Retrospec-
tive Evaluation and Assessment of Therapies in AF); ATRIA-CVRN — the AnTicoagulation and Risk factors In Atrial fibrillation-Cardiovascular 
Research Network; RACE II — Rate Control Efficacy in Permanent AF; ROCKET-AF — the rivaroxaban once daily, oral, direct factor Xa  
inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation; NHIRD — the National Health 
Insurance Research Database; PALLAS — The Permanent Atrial FibriLLation Outcome Study using dronedarone on top of standard therapy; 
ADONIS — The American–Australian–African trial with DronedarONe In atrial fibrillation or flutter Patients for the maintenance of Sinus 
rhythm; ANDROMEDA — the ANtiarrhythmic trial with DROnedarone in Moderate-to-severe CHF Evaluating morbidity DecreAse; ATHENA — 
A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular 
Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter; ORBIT-AF — the Outcomes Registry for Better Informed 
Treatment of Atrial Fibrillation; AUPD — Aarhus University Prescription Database
Figure 1. Forest plot of the included studies. The computed weighted hazard ratios are depicted as boxes proportional 
to the size of the study. The bars depict the 95% confidence intervals (CI). Studies favoring use of digoxin are on the 
right hand side of the center line of no effect, while the studies against the use of digoxin are on the left hand side of 
the center line of no effect.
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Figure 2. Forest plot of subgroup analyses of randomized controlled clinical trials (sensitivity analysis). The computed 
weighted hazard ratios are depicted as boxes proportional to the size of the study. The bars depict the 95% confidence 
intervals (CI). Studies favoring use of digoxin are on the right hand side of the center line of no effect, while the studies 
against the use of digoxin are on the left hand side of the center line of no effect.
insignificant (c2: 7.10, df = 6, p = 0.31; I2 = 16%). 
The AF Follow-Up Investigation of Rhythm Man-
agement (AFFIRM) trial had 2 published analyses. 
For primary analysis, we used the study with the 
larger subsample [15], however in a sensitivity 
analysis with the smaller sub-study [16], there 
was no significant difference in the pooled HRs 
(1.27; 95% CI 1.19–1.36 vs. 1.20; 95% CI 1.18–1.22, 
p for interaction = 0.11). Other subgroup analyses 
are shown in Supplementary Table 2. The risk of 
cardiovascular mortality associated with digoxin 
use was available in 9 studies. In a random effects 
model, digoxin use was associated with a 21% in-
creased risk of mortality (pooled HR: 1.21; 95% CI 
1.12–1.30, p < 0.001) with significant inter-study 
heterogeneity (I2 = 74%, p < 0.001) (Suppl. Fig. 2). 
Removal of studies with < 30% of HF showed no 
heterogeneity (p > 0.1).
In a stratified analysis, the risk of mortality 
for individuals using digoxin in AF patients with 
HF was 21% higher (pooled HR: 1.21; 95% CI 
1.07–1.36, p = 0.002; Fig. 3A) compared with par-
ticipants who did not use digoxin. The risk of mor-
tality for individuals without HF was 47% higher for 
digoxin users (pooled HR: 1.47; 95% CI 1.25–1.73, 
p < 0.001; Fig. 3B) than non-digoxin users.
Due to heterogeneity, a funnel plot was cre-
ated to assess publication bias (Suppl. Fig. 3). 
The funnel plot showed minimal asymmetry that 
was quantified statistically by Egger’s regression 
intercept (intercept: 1.16; 95% CI –0.76–3.08, 
df = 14, 1-tailed p-value: 0.11). Classical fail safe N 
was 1507, suggesting that there would need to be 
1507 null studies with mean HR of 1.00 added to 
the analysis before the pooled effect would become 
non-significant. A more conservative method, Or-
win’s fail-safe N method was used to estimate the 
number of studies that would need to be added to 
the meta-analysis to make the pooled effect non-
significant. For this reason, we assumed a mean HR 
of less than 0.90 for the potentially missing studies. 
Using this criterion, at least 29 studies would be 
needed to make the association between digoxin 
use and mortality non-significant. Using a trim and 
fill method, we needed to trim a study on the left of 
the mean which changed the pooled estimate from 
1.28 (95% CI 1.20–1.37) to 1.26 (95% CI 1.18–1.35). 
There was no asymmetry on the right of the mean.
Additional analyses showed that there was 
a temporal effect present with more recent studies 
having lower effect sizes than older studies, how-
ever the direction and point estimate for the pooled 
HRs remained significant (Suppl. Fig. 4). When we 
removed one study from the analysis at each step 
of the analysis, the pooled estimate remained sig-
nificant (Suppl. Fig. 5). In meta-regression analysis, 
proportion of HF in studies was inversely associated 
with risk of mortality associated with digoxin (slope: 
–0.008; 95% CI from –0.01 to –0.002, p = 0.02, 
Suppl. Fig. 6) suggesting HF modifies the risk of 
mortality and digoxin use.
Discussion
This comprehensive meta-analysis included 
501,681 individuals and assessed the effect of di-
goxin use in AF patients in 9 randomized clinical 
trials and 10 observational cohorts. There were 
three main findings: 1) digoxin users with AF had 
a 27% increased risk of all-cause mortality, 2) di-
goxin users with AF had a 21% increased risk of 
cardiovascular mortality, and 3) digoxin users with 
AF who did not have HF had a relatively stronger 
association with risk of all-cause mortality (47% 
vs. 21%, p for interaction = 0.058) than digoxin 
users with HF.
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Several reports have examined the negative 
consequences of digoxin use resulting in a signifi-
cant drop in digoxin use in acute myocardial infarc-
tion during the last two decades [17, 18]. Data sup-
porting its use in chronic systolic HF have mainly 
come from two withdrawal studies [19, 20], and 
the Digitalis Investigation Group trial that showed 
an absolute increase of 1.9% in cardiac death with 
digitalis (not including HF-related death) [21]. 
However, due to concomitant absolute reduction in 
HF-related mortality by 1.6%, the overall primary 
endpoint was not significant.
The aforementioned studies found an increased 
risk of all-cause mortality in conditions that are not 
limited to AF. Our results support these prior find-
ings and extend prior work to show an increased 
risk of all-cause and cardiovascular mortalities exist 
for AF patients who use digoxin. Although the risks 
for the adverse outcomes examined were attenuated 
when we examined patients with HF, there was 
still a suggestion of 21% increased risk of all-cause 
mortality in these patients.
We also observed a downward temporal trend 
in reduced risk of mortality associated with digoxin 
use over the last 15 years. The reason for this dif-
ference is speculative but possibly related to the 
improved management of cardiovascular disease 
over the last decade [22]. Several of these studies 
have included individuals over periods of time, and 
have found a decreasing trend towards reduced 
prescription of digoxin by the clinicians [23].
The exact mechanism underlying increased 
mortality risk observed with digoxin is unknown. 
Most of the reviewed studies did not evaluate 
the serum digoxin levels with mortality. Serum 
digoxin levels were significantly higher in those 
who died (1.151 vs. 0.935 ng/mL, p < 0.001) in 
one of the studies [24]. Renal function regulates 
serum digoxin levels and a subgroup analysis of AF-
-FIRM demonstrated increased mortality in digoxin 
Figure 3. Forest plot of studies including atrial fibrillation patients with heart failure showing association of digoxin 
use with all-cause mortality. The computed weighted hazard ratios are depicted as boxes proportional to the size of 
the study. The bars depict the 95% confidence intervals (CI). Studies favoring use of digoxin are on the right hand 
side of the center line of no effect, while the studies against the use of digoxin are on the left hand side of the center 
line of no effect; A. Heterogeneity becomes insignificant after removing, LIFE, RIKS-HIA, RACE-II and Pastori study, 
I2 = 40%, p = 0.14; B. Heterogeneity becomes insignificant after removing, LIFE, ATRIA-CVRN, RIKS-HIA and Pastori 
study, I2 = 1%, p = 0.41.
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users (HR: 1.28; 95% CI 1.25–1.31; p < 0.001). 
Thus it can be speculated that higher serum levels 
of digoxin are related with the pathogenesis. Sud-
den cardiac death was also observed to be high 
in ROCKET-AF study and LIFE study in digoxin 
users. Sudden cardiac death is frequently due to 
fatal arrhythmia [25]. Digoxin was shown to in-
crease arrhythmia-related deaths by 61% in post 
hoc analysis of AFFIRM trial [15]. Furthermore, we 
identified association of digoxin with cardiovascular 
mortality as well suggesting this observed mortal-
ity has cardiac basis rather than non-cardiovascular 
cause. This has been also previously demonstrated 
in a study without patients with AF [15]. Digoxin 
was shown to increase arrhythmia-related deaths 
by 61% in post hoc analysis of AFFIRM trial [15].
This study has several implications regarding 
management of AF in patients with and without HF. 
The burden of AF is increasing at dramatic pace 
with doubling AF by 2050. The annual mortality 
risk in AF is 3.84%, of which 37.4% occur due to 
cardiovascular conditions [26]. This analysis shows 
that at least 1/4th of this risk is probably related to 
digoxin. A possible reduction in prescription of di-
goxin to these individuals may potentially improve 
overall survival of these patients. Even though the 
results have been consistent, this study still is 
limited by its exploratory design and thus calls for 
a randomized trial of digoxin in AF patients, with and 
without HF, to demonstrate its safety. However, 
it may be difficult to perform a randomized study 
at this point; a withdrawal study might be more 
suitable to confirm our findings. Additionally, this 
study suggests that there is a need to revisit the 
management guidelines of AF. There have been 
several changes in the management of HF and AF 
in the last decade. Management of AF in the light 
of recent evidence-based therapies may eventu-
ally lead to discarding the use of digoxin in these 
particular patients.
Limitations of the study
The current analysis should be interpreted in 
the context of several limitations. We did not have 
access to the source data for any of the studies 
used and the analysis was based on effect sizes 
and confidence intervals obtained from published 
studies. There was a significant heterogeneity in 
the population which remained unexplained and 
possibly is due to differences in the study samples 
examined. Also, the included studies from clinical 
trials were performed as post hoc analyses and 
potentially introduced bias into the current study. 
Bias by indication also is a significant limitation 
that should be considered while interpreting these 
results. Additionally, we were not able to assess 
the type of AF (e.g., paroxysmal, persistent, per-
manent) and the results may vary when accounting 
for this aspect of the arrhythmia. The exact doses 
of digoxin and other AF medications were unknown 
and possibly influenced the relationship between 
digoxin and the outcomes examined (e.g., drug- 
-drug interactions) [27].
Conclusions
The results from this pooled analysis sug-
gest that digoxin use in AF is associated with 
an increased risk of all-cause and cardiovascular 
mortalities. Special consideration should be used 
by clinicians who use digoxin for rate control in pa-
tients with AF. Further study is needed to elucidate 
the underlying mechanism related to the increased 
risk of adverse events associated with digoxin.
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Supplementary Table 1. Number of participants in the clinical studies and follow-up duration.
Study Year Digoxin  
users
Non digoxin  
users
Atrial  
fibrillation
Deaths Total Follow-up
LIFE [28] 1997 116 8,715 701 151 8,831 4.7 years
AFFIRM [15] 2001 2,153 1,905 4,058 666 4,058 3.5 years
SPORTIF [29] 2002 3,911 3,418 7,329 396 7,329 1.5 years
RIKS-HIA [4] 2003 16,426 44,338 60,764 7,520 60,764 1 years
SCAF [5] 2007 802 2,022 2,824 1,038 2,824 4.6 years
Fauchier [23] 2007 591 678 1,269 247 1,269 881 days
TREAT-AF [30] 2008 28,679 93,786 122,465 28,723 122,465 0.4 years
ATRIA-CVRN [24] 2009 4,858 22,430 27,288 1,140 27,288 1.17 years
RACE II [31] 2009 284 324 608 76 608 3 years
ROCKET-AF [32] 2010 2,948 11,223 14,171 1,214 14,171 3 years
NHIRD [33] 2010 829 3,952 3,952 170 4,781 2.3 years
PALLAS [34] 2010 1,070 2,166 3,236 31 3,236 117 days
ADONIS [14] 2010 118 511 629 13 629 370 days
ANDROMEDA [14] 2010 135 105 240 17 240 228 days
ATHENA [14] 2010 629 3,639 4,268 153 4,268 651 days
ORBIT-AF [35] 2011 2,948 6,671 9,619 178 9,619 3 years
Quebec study [27] 2012 38,381 101,730 140,111 79,312 140,111 3 years
AUPD study [36] 2012 6,929 81,386 8,880 12,826 88,315 365 days
Pastori study [37] 2013 171 644 815 85 815 33.2 months
LIFE — The Losartan Intervention For Endpoint reduction in hypertension; AFFIRM — the AF Follow-Up Investigation of Rhythm Management; 
SPORTIF — the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation; RIKS-HIA — the Registry of Information and Knowl-
edge about Swedish Heart Intensive care Admissions; SCAF — the Stockholm Cohort-Study of Atrial Fibrillation; TREAT-AF — The Retrospec-
tive Evaluation and Assessment of Therapies in AF); ATRIA-CVRN — the AnTicoagulation and Risk factors In Atrial fibrillation-Cardiovascular 
Research Network; RACE II — Rate Control Efficacy in Permanent AF; ROCKET-AF — the rivaroxaban once daily, oral, direct factor Xa  
inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation; NHIRD — the National Health 
Insurance Research Database; PALLAS — The Permanent Atrial FibriLLation Outcome Study using dronedarone on top of standard therapy; 
ADONIS — The American–Australian–African trial with DronedarONe In atrial fibrillation or flutter Patients for the maintenance of Sinus 
rhythm; ANDROMEDA — the ANtiarrhythmic trial with DROnedarone in Moderate-to-severe CHF Evaluating morbidity DecreAse; ATHENA — 
A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular 
Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter; ORBIT-AF — the Outcomes Registry for Better Informed 
Treatment of Atrial Fibrillation; AUPD — Aarhus University Prescription Database
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Supplementary Figure 1. Flowchart of the included studies.
Supplementary Figure 2. Random effects model showing risk of cardiovascular disease with digoxin use (n = 9 studies).
Supplementary Figure 3. Funnel plot showing publication bias.
Supplementary Table 2. Subgroup analyses by various characteristics of studies.
Risk of mortality
Hazard ratio (95% CI)
P* Risk of cardiovascular mortality
Hazard ratio (95% CI)
P*
Age > 70:  
1.20 (1.18–1.21)
£ 70:  
1.33 (1.24–1.42)
0.003 > 70:  
1.17 (1.05–1.30)
£ 70:  
1.26 (1.13–1.41)
0.34
Follow up > 2 years:  
1.22 (1.17–1.28)
£ 2 years:  
1.20 (1.18–1.22)
0.67 > 2 years:  
1.21 (1.12–1.31)
£ 2 years:  
1.20 (0.88–1.63)
0.05
BB use > 50%:  
1.21 (1.13–1.29)
£ 50%:  
1.20 (1.18–1.22)
0.22 > 50%:  
1.20 (1.10–1.30)
£ 50%:  
1.33 (1.06–1.68)
0.44
Year 2010 During and after: 
1.16 (1.14–1.18)
Before:  
1.28 (1.25–1.30)
< 0.001 During and after: 
1.23(1.11–1.37)
Before:  
1.18 (1.06–1.32)
0.59
IHD > 20%:  
1.36 (1.27–1.45)
£ 20:  
1.19 (1.18–1.21)
< 0.001 > 20%:  
1.29 (1.15–1.44)
£ 20%: 
1.16 (1.04–1.28)
0.17
HF > 20%:  
1.22 (1.16–1.28)
£ 20%:  
1.20 (1.18–1.22)
0.54 > 20%:  
1.21 (1.11–1.33)
£ 20%:  
1.20 (1.05–1.37)
0.92
DM > 25%:  
1.25 (1.23–1.28)
£ 25%:  
1.17 (1.16–1.19)
< 0.001 > 25%:  
1.23 (1.13–1.35)
£ 25%:  
1.12 (0.97–1.30)
0.28
Trails Clinical only:  
1.28 (1.16–1.42)
Observations only: 
1.20 (1.18–1.21)
0.21 Clinical only:  
1.20 (1.07–1.36)
Observations only: 
1.21 (1.10–1.34)
0.92
*P value for interaction; BB — beta-blocker; CI — confidence interval; DM — diabetes mellitus; HF — heart failure; IHD — ischemic heart disease
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Supplementary Figure 4. Temporal effect shown by point estimates with addition of each study. Each point estimate 
is the cumulative hazard ratio in a way that the first study (LIFE 1997) showed only point estimate of LIFE 1997. The 
subsequent point estimate is the pooled estimate of LIFE 1997 and AFFIRM 2001, the third estimate is the pooled 
estimate of LIFE 1997, AFFIRM 2001 and SPORTIF III and IV 2002, and so on. Therefore, a decrement in the pooled 
estimate demonstrates a temporal decline in hazard ratio in published studies.
Supplementary Figure 5. One-study removal plot showing consistent estimates with removal of each study with 
each estimate. The corresponding hazard ratio in front of each study is the pooled hazard ratio after removal of that 
particular study. For example, the hazard ratio in front of LIFE 1997 is the pooled hazard ratio of all the other stud-
ies without including LIFE 1997. Such a plot demonstrates if one of the study has significant influential effect on the 
pooled estimates of meta-analysis. In a possible scenario, if a particular influential study is removed, the correspond-
ing pooled hazard ratio may become insignificant. Here all of the corresponding pooled hazard ratios are significant, 
suggesting that none of the studies had particular influential effect on the pooled estimate.
Supplementary Figure 6. Meta-regression plot showing a downsloping regression curve of hazard ratio across studies 
with increasing prevalence of heart failure patients for association of digoxin with mortality.
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